October 29, 2015
A New Jersey federal judge on Thursday dismissed a False Claims Act against Genentech Inc. regarding its cancer drug Avastin, holding a whistleblower didn't show the drug's advertised claims were false and the Centers for Medicare & Medicaid Services and U.S. Food and Drug Administration properly approved the drug.